Study of BB-025, Alone and After BB-031, in Healthy Volunteers

The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent. In the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms. In the second part of the study, participants will receive a single dose of BB-031 and then be given either BB-025 or placebo. These participants will also be followed for 28 days to check if they have any symptoms.

NCT Number	NCT07202663
Lead Sponsor	Basking Biosciences, Inc.
Conditions	Pharmacodynamics, Pharmacokinetics, Healthy Volunteers
Enrollment	72 participants
Start Date	2025-11-05
Primary Completion	2026-03-18 (estimated)
Study Completion	2026-03-18 (estimated)
Updated on ClinicalTrials.gov	2026-04-06